No financial support was received for this work.
Celiac Plexus Neurolysis for Abdominal Cancer Pain: A Systematic Review
Article first published online: 26 JUN 2013
Wiley Periodicals, Inc
Volume 14, Issue 8, pages 1140–1163, August 2013
How to Cite
Nagels, W., Pease, N., Bekkering, G., Cools, F. and Dobbels, P. (2013), Celiac Plexus Neurolysis for Abdominal Cancer Pain: A Systematic Review. Pain Medicine, 14: 1140–1163. doi: 10.1111/pme.12176
The work has not been presented at any meeting.
- Issue published online: 19 AUG 2013
- Article first published online: 26 JUN 2013
- Celiac Plexus Neurolysis;
- Systematic Review
This systematic review assesses the effectiveness and side effects of celiac plexus neurolysis (CPN) in the treatment of upper abdominal cancer pain, and evaluates whether there are any differences between the percutaneous and endoscopic ultrasound-guided (EUS) denervation techniques.
Five databases were searched, expanded by assessing the reference lists of all retrieved papers. Sixty-six publications fulfilled the inclusion/exclusion criteria and were included in the systematic review. Randomized controlled trials were available for the percutaneous CPN, and therefore meta-analyses were performed for pain, opioid consumption, and specific side effects. The quality of life data were too heterogeneous to be assessed by a meta-analysis, and evidence for EUS CPN could only be evaluated by observational studies.
Meta-analyses show that percutaneous CPN significantly improves pain in patients with upper abdominal cancer, with a decrease in opioid consumption and side effects. It is unclear whether there is any change in quality of life. Case series suggest that EUS CPN improves pain. No conclusion can be made about EUS CPN's influence on opioid consumption. Although CPN is a safe procedure, side effects and complications can occur with both the percutaneous and EUS techniques.
Following this review, evidence suggests that CPN should be considered in patients with upper abdominal cancer where the pain is not adequately controlled with systemic analgesics or when significant opioid-induced side effects are present. The percutaneous approach remains the standard technique as robust evidence for EUS CPN is lacking.